Ibrutinib Becomes First FDA-Approved Drug for Chronic Graft-Versus-Host Disease

| August 11, 2017 | 0 Comments
Ibrutinib Becomes First FDA-Approved Drug for Chronic Graft-Versus-Host Disease

A drug used to treat several blood cancers, ibrutinib, has been approved by FDA to treat chronic graft-versus-host disease, making it the first approved therapy for this potentially fatal side effect of cancer-related stem cell transplants.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply